Literature DB >> 8210722

Decreases in serum cholesterol levels in advanced lung cancer.

S Umeki1.   

Abstract

Serum lipid concentrations, including triglycerides, free fatty acids, phospholipids, low-density lipoproteins, total cholesterol, high-density lipoprotein (HDL) cholesterol and lipoprotein fractions, were investigated in 43 male patients with advanced nonresectable lung cancer and 37 age- and sex-matched healthy male controls. The cancer patients as a group demonstrated significantly lower total cholesterol and HDL cholesterol as compared with the healthy controls. There were no significant differences between the various fractions of lipoproteins in the two patient groups. These results suggest hypocholesterolemia including decreased serum HDL cholesterol in advanced lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8210722     DOI: 10.1159/000196195

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  19 in total

1.  Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

Authors:  K M Wasan; F W Strobel; S C Parrott; M Lynn; W J Christ; L D Hawkins; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Anna M Kucharska-Newton; Wayne D Rosamond; Jane C Schroeder; Ann Marie McNeill; Josef Coresh; Aaron R Folsom
Journal:  Lung Cancer       Date:  2008-03-14       Impact factor: 5.705

3.  Cholesterol esters as growth regulators of lymphocytic leukaemia cells.

Authors:  M F Mulas; C Abete; D Pulisci; A Pani; B Massidda; S Dessì; A Mandas
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

4.  Rat and rabbit plasma distribution of free and chylomicron-associated BIRT 377, a novel small molecule antagonist of LFA-1-mediated cell adhesion.

Authors:  K M Wasan; M Ramaswamy; L Holtorf; A A Jayaraj; D J Hauss
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

5.  Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer.

Authors:  Jiyoung Ahn; Unhee Lim; Stephanie J Weinstein; Arthur Schatzkin; Richard B Hayes; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-11-03       Impact factor: 4.254

6.  Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.

Authors:  Kishor M Wasan; Olena Sivak; Richard A Cote; Aaron I MacInnes; Kathy D Boulanger; Melvyn Lynn; William J Christ; Lynn D Hawkins; Daniel P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  Lipid profile in leukemia and Hodgkin's disease.

Authors:  P P Naik; M S Ghadge; A S Raste
Journal:  Indian J Clin Biochem       Date:  2006-09

8.  The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer.

Authors:  Donovan McGrowder; Cliff Riley; Errol Y St A Morrison; Lorenzo Gordon
Journal:  Cholesterol       Date:  2010-12-23

9.  Hypolipidemia: a word of caution.

Authors:  Rr Elmehdawi
Journal:  Libyan J Med       Date:  2008-06-01       Impact factor: 1.657

10.  High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma.

Authors:  Pei-Dong Chi; Wen Liu; Hao Chen; Jing-Ping Zhang; Yuehao Lin; Xin Zheng; Wanli Liu; Shuqin Dai
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.